|Bid||1,550.00 x 175400|
|Ask||1,595.00 x 417900|
|Day's Range||1,567.00 - 1,592.40|
|52 Week Range||1,269.80 - 1,648.80|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||21.69|
|Earnings Date||May 1, 2019|
|Forward Dividend & Yield||0.92 (5.95%)|
|1y Target Est||1,644.50|
Announcement: Moody's announces completion of a periodic review of ratings of Innoviva, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Innoviva, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth drivers On its fourth-quarter earnings conference call, GlaxoSmithKline (GSK) highlighted the prioritization of R&D (research and development)
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)EPS guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for non-GAAP (generally accepted accounting principles) EPS
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Revenue guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for revenue of $43.2 billion–$44.7 billion, a YoY
The treatment, the first generic of Advair, is approved in three doses and will be priced between $93.71 and $153.14, the company said. Advair targets certain patients with asthma or chronic obstructive pulmonary disease and brought in revenue of about $4.19 billion in 2017 for the London-listed GSK. Mylan received approval for the treatment from the U.S. Food and Drug Administration last month.
Drugmakers, wholesalers and pharmacies across Europe have worked for more than four years on a system based on a shared database and tamper-proof packages with barcodes that will go live on Saturday, to fulfil the European Union's Falsified Medicines Directive (FMD). "It would be an absolute travesty if NHS patients aren't part of a system specifically designed to protect them. The British government, which says that about three-quarters of medicines used by the state-run National Health Service (NHS) come via the EU, has outlined plans to ensure Britain has an extra six weeks of drug supplies in the event of a no-deal Brexit.
GlaxoSmithKline PLC said it expects profit to fall this year as it boosts spending on developing new cancer drugs and faces generic competition for its best-selling inhaler product for the first time. The British pharmaceutical giant on Wednesday reported upbeat full-year earnings but warned that adjusted earnings per share—a measure closely watched by analysts—could fall by 5% to 9% in 2019. Glaxo, under pressure from investors to replenish its pipeline, is determined to bolster its presence in the competitive cancer market, focusing on drugs designed to aid the body’s immune response to tumors.
Eli Lilly stock undercut a buy point Wednesday after fourth-quarter earnings lagged estimates. But shares of fellow drug giant GlaxoSmithKline stock popped on its quarterly sales beat.
Chief executive Emma Walmsley has been streamlining operations and spinning off or selling units, including the company's consumer health division, in order to focus on expanding GSK's drug pipeline and developing vaccines. Sales of Shingrix, the company's shingles vaccine launched in 2017, more than doubled in the fourth quarter of 2018 to 221 million pounds, but sales of asthma treatment Advair, which has fueled much of the company's respiratory drugs franchise, fell 20 percent. As it seeks to offset patent expiries on some of its key drugs, GSK on Tuesday agreed to pay up to 3.7 billion euros to Germany's Merck KGaA for the rights to a next-generation immunotherapy.
On a per-share basis, the Brentford Middlesex, Britain-based company said it had profit of 63 cents. Earnings, adjusted for one-time gains and costs, came to 79 cents per share. The results surpassed Wall ...
GlaxoSmithKline Plc forecast 2019 earnings above market expectations as sales of its new shingles vaccine boosted quarterly results, soothing concerns that Britain's largest drugmaker was running out of blockbuster products. Chief executive Emma Walmsley has been streamlining operations and spinning off or selling units, including the company's consumer health division, in order to focus on expanding GSK's drug pipeline and developing vaccines. Sales of Shingrix, the company's shingles vaccine launched in 2017, more than doubled in the fourth quarter of 2018 to 221 million pounds, but sales of asthma treatment Advair, which has fueled much of the company's respiratory drugs franchise, fell 20 percent.
GlaxoSmithKline said fourth-quarter profit before tax more than tripled, but guided for a fall in adjusted earnings per share in the year ahead on the impact of generic competition.
Britain's biggest drugmaker GlaxoSmithKline Plc on Wednesday said it expects full-year adjusted profit to be hurt by new competition for its blockbuster asthma drug Advair. GSK reported adjusted earnings ...
EMD Serono revealed plans to build a new 145,000-square-foot facility to support its immune-oncology work, particularly clinical testing of a new cancer-fighting drug partnered with GlaxoSmithKline.
reported a better than expected 14 per cent increase in earnings for the final quarter of 2018, but said competition to its blockbuster Advair asthma drug meant earnings would fall this year. The company on Wednesday reported adjusted fourth-quarter earnings per share at 31.2p a share, up 14 per cent, on a 7 per cent increase in quarterly sales of £8.2bn. GSK said it expected 2019 adjusted earnings per share to decline between 5 and 9 per cent, a reflection of the recent approval of a generic competitor to Advair in the US.
On Wednesday, Feb. 6, GlaxoSmithKline (NYSE: GSK ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Based on management's ...
The deal includes a $343 million upfront payment payment and potential future milestone payments of nearly $3.9 billion.
GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy. Merck will receive an upfront payment of 300 million euros for the drug - known as M7824, or bintrafusp alfa - and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer, the two companies said in statements on Tuesday. Merck could also get up to a further 2.9 billion euros, depending on commercial milestones, for a total deal value of as much as 3.7 billion euros.
U.K.-based GlaxoSmithKline plc and Germany-based Merck KGaA are partnering with each other to develop and commercialize a therapy for patients with advanced non-small cell lung cancer (NSCLC) in a deal worth up to $4.23 billion, the companies announced Tuesday. The therapy, dubbed M7824, is a bifunctional antibody designed to simultaneously target two pathways in the body that serve as immune checkpoints: one that involves a protein called transforming growth factor-β and another involving the programmed death ligand-1 (PD-L1). Under the terms of the deal, Merck KGaA will receive an upfront payment of €300 million, or $342.75 million, and will be eligible for potential development milestone payments of up to €500 million, or $571.25 million. Merck KGaA will also be eligible for further payments upon approval and commercial milestones of up to €2.9 billion, or $3.31 billion, for a total potential deal value up to €3.7 billion, or $4.23 billion. Both GSK and Merck KGaA will be involved in development and commercialization, and all profits and costs will be shared equally, the companies said. The partnership is another step in GSK's oncology pipeline development. The company recently acquired Tesaro, an oncology-focused company based in Waltham, Mass. M7824 is currently in Phase 1 studies for the treatment of solid tumors, as well as a randomised Phase 2 trial to evaluate the safety and efficacy of M7824 compared with pembrolizumab as a first-line treatment in patients with PD-L1-expressing advanced NSCLC. Shares of GSK have gained 0.6% in the year to date, while shares of Merck KGaA have gained 4.4%. The S&P 500 has gained 8.7%.
Merck, the German drug and chemicals group, and GlaxoSmithKline have agreed a deal in which the UK pharmaceutical company will pay up to €3.7bn for the rights to a new type of immunotherapy for difficult-to-treat cancers. Merck believes it has developed a novel dual-function antibody for certain cancers, including non-small cell lung cancer. “This is a deal that will allow the co-development, co-commercialisation for a novel class of immunology,” Belén Garijo, chief executive of the healthcare division at Merck, told the Financial Times.